|OncoCyte Provides Corporate Update and Reports Fourth Quarter and Full Year 2018 Financial Results|
On track for commercial availability of DetermaVu™ in 2H 2019
Conference Call Today at
“OncoCyte has made outstanding progress since our last quarterly update to investors, reporting positive results from our DetermaVu™ R&D Validation Study which demonstrated that DetermaVu™ is a commercially viable assay with the potential to change the treatment paradigm in lung cancer diagnostics,” said
Remaining Validation Pathway for DetermaVu™:
Fourth Quarter and Annual 2018 Financial Results
For the quarter ended
Operating expenses for the three months ended
The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.
Research and development expenses for the fourth quarter of 2018 were
General and administrative expenses for the fourth quarter of 2018 were
General and administrative expenses for the year ended
Sales and marketing expenses for the fourth quarter of 2018 were
The Company will host a conference call today,
The dial-in number in the U.S./
DetermaVu™ is being developed as an intermediate step to confirm the absence of cancer after imaging modalities (LDCTs) that detect suspicious lung nodules and before downstream invasive procedures that determine if the nodules are malignant.
DetermaVu™ has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a recent
DetermaVu™ is a trademark of
OncoCyte Forward Looking Statements
Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for
Non-GAAP Financial Measures
This earnings release includes operating expenses prepared in accordance with accounting principles generally accepted in
Furthermore, management uses these non-GAAP financial measures in the aggregate to establish budgets and operational goals, to manage OncoCyte’s business and to evaluate its performance and its programs.